NCT04986982View on ClinicalTrials.gov

OpiCapone Effect on Motor Fluctuations and pAiN

PHASE4CompletedINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

February 25, 2021

Primary Completion Date

February 16, 2024

Study Completion Date

February 16, 2024

Conditions
Parkinson Disease
Interventions
DRUG

Opicapone 50 mg

Opicapone (BIA 9-1067) 50 mg hard capsules. Oral administration, once daily, at least 1 hour before or after the last daily dose of L-dopa/DDCI

OTHER

Placebo

Matching placebo hard capsules. Oral administration, once daily, at least 1 hour before or after the last daily dose of L-dopa/DDCI

Trial Locations (1)

SE5 9RT

The Maurice Wohl Clinical Neuroscience Institute - King's College Hospital, London

All Listed Sponsors
lead

Bial - Portela C S.A.

INDUSTRY

NCT04986982 - OpiCapone Effect on Motor Fluctuations and pAiN | Biotech Hunter | Biotech Hunter